Abstract | BACKGROUND: METHODS: RESULTS: At median follow-up of 90 days, 52/118 (44%) and 17/125 (14%) developed CKD and hypertension, respectively. Biomarker prediction for 3-month CKD was low to modest; NGAL combined with KIM-1 at EV discharge yielded the highest AUC (0.67, 95% CI 0.57-0.77). Biomarker prediction of 3-month hypertension was stronger, but modest; the highest AUC was from combining EV pre-infusion NGAL and TIMP-2* IGFBP-7 (0.71, 95% CI 0.62-0.80). When EV pre-infusion NGAL and TIMP-2* IGFBP-7 were added to the 3-month hypertension clinical predictive model, AUCs increased from 0.81 (0.72-0.91) to 0.89 (0.83-0.95) (p<0.05). CONCLUSIONS: Tubular injury biomarkers we studied were individually not strong predictors of 3-month post- cisplatin kidney outcomes. Adding biomarkers to existing clinical prediction models may help predict post- therapy hypertension and identify higher kidney-risk patients.
|
Authors | Ryan S Huang, Kelly R McMahon, Stella Wang, Hayton Chui, Asaf Lebel, Jasmine Lee, Vedran Cockovski, Shahrad Rod Rassekh, Kirk R Schultz, Tom D Blydt-Hansen, Geoffrey D E Cuvelier, Cherry Mammen, Maury Pinsk, Bruce C Carleton, Ross T Tsuyuki, Colin J D Ross, Ana Palijan, Michael Zappitelli, Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group* |
Journal | Kidney360
(Kidney360)
(Apr 26 2024)
ISSN: 2641-7650 [Electronic] United States |
PMID | 38668904
(Publication Type: Journal Article)
|
Copyright | Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology. |